Savara Inc Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Savara Inc (SVRA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 19.28 million shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- Savara Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 19.28M shares, a 11.36% increase year-over-year.
- Savara Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 17.31M shares, a 28.24% increase year-over-year.
- Savara Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 13.50M shares, a 26.66% increase year-over-year.
- Savara Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 10.66M shares, a 41.24% increase year-over-year.
- Savara Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 20.23M shares, a 10.47% increase from fiscal 2024.
- Savara Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 18.31M shares, a 38.72% increase from fiscal 2023.
- Savara Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 13.20M shares, a 32.61% increase from fiscal 2022.
- Savara Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 9.95M shares, a 31.50% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | 19.28M shares 10-Q · filed 2026-08-11 | 19.75M shares 10-Q · filed 2026-05-12 | |||||
| 2025-12-31 | 20.23M shares 10-K · filed 2026-03-13 | ||||||
| 2025-09-30 | 17.38M shares 10-Q · filed 2025-11-12 | ||||||
| 2025-06-30 | 17.31M shares 10-Q · filed 2025-08-13 | ||||||
| 2025-03-31 | 17.31M shares 10-Q · filed 2026-08-11 | 17.36M shares 10-Q · filed 2025-05-13 | |||||
| 2024-12-31 | 18.31M shares 10-K · filed 2026-03-13 | ||||||
| 2024-09-30 | 13.31M shares 10-Q · filed 2025-11-12 | ||||||
| 2024-06-30 | 13.37M shares 10-Q · filed 2025-08-13 | ||||||
| 2024-03-31 | 13.50M shares 10-Q · filed 2025-05-13 | ||||||
| 2023-12-31 | 13.20M shares 10-K · filed 2025-03-27 | ||||||
| 2023-09-30 | 10.91M shares 10-Q · filed 2024-11-12 | ||||||
| 2023-06-30 | 11.00M shares 10-Q · filed 2024-08-12 | ||||||
| 2023-03-31 | 10.66M shares 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | 9.95M shares 10-K · filed 2024-03-07 | ||||||
| 2022-09-30 | 7.02M shares 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | 7.28M shares 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | 7.55M shares 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | 7.57M shares 10-K · filed 2023-03-30 | ||||||
| 2021-09-30 | 5.58M shares 10-Q · filed 2022-11-10 | ||||||
| 2021-06-30 | 9.03M shares 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | 9.42M shares 10-Q · filed 2022-05-11 | ||||||
| 2020-12-31 | 38.58M shares 10-K · filed 2022-03-30 | ||||||
| 2020-09-30 | 37.02M shares 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | 37.83M shares 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | 37.91M shares 10-Q · filed 2021-05-13 | ||||||
| 2019-12-31 | 37.99M shares 10-K · filed 2021-03-10 | ||||||
| 2019-09-30 | 4.25M shares 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | 4.29M shares 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | 4.18M shares 10-Q · filed 2020-05-07 | ||||||
| 2018-12-31 | 4.14M shares 10-K · filed 2020-03-12 | ||||||
| 2018-09-30 | 3.70M shares 10-Q · filed 2019-11-07 | 4.47M shares 10-Q · filed 2018-11-07 | |||||
| 2018-06-30 | 2.77M shares 10-Q · filed 2019-08-08 | 3.55M shares 10-Q · filed 2018-08-09 | |||||
| 2018-03-31 | 3.29M shares 10-Q · filed 2019-05-09 | 4.06M shares 10-Q · filed 2018-05-09 | |||||
| 2017-12-31 | 4.09M shares 10-K · filed 2019-03-13 | ||||||
| 2017-09-30 | 3.63M shares 10-Q · filed 2018-11-07 | ||||||
| 2017-06-30 | 3.08M shares 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | 9.69M shares 10-Q · filed 2018-05-09 | ||||||
| 2016-12-31 | 9.84M shares 10-K · filed 2018-03-14 | ||||||
| 2016-09-30 | 8.93M shares 10-Q · filed 2017-11-08 | ||||||
| 2016-06-30 | 8.56M shares 10-Q · filed 2017-08-09 | ||||||
| 2015-12-31 | 8.22M shares 10-K · filed 2018-03-14 | ||||||
| 2013-12-31 | 37.32M shares 10-K · filed 2014-03-26 | ||||||
| 2012-12-31 | 20.21M shares 10-K · filed 2014-03-26 | ||||||
| 2011-12-31 | 10.59M shares 10-K · filed 2013-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |